Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis [Phase 1, Phase 2]

View source ↗

Summary

Chipscreen Biosciences is conducting a Phase 1/2 study to evaluate the efficacy and safety of CS32582 in adults with moderate to severe plaque psoriasis, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• CS32582

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Plaque Psoriasis | Phase 1, Phase 2 | Status: RECRUITING